Explore
Trendline
Gilead Sciences Achieves New All-Time Highs Driven by Strong HIV and Liver Disease Portfolio Growth
Gilead Sciences Achieves New All-Time Highs Driven by Strong HIV and Liver Disease Portfolio Growth
Read More
Trendline
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Read More
Trendline
Mondelez International Reaffirms 2026 Outlook Amidst Shifting Revenue Dynamics
Mondelez International Reaffirms 2026 Outlook Amidst Shifting Revenue Dynamics
Read More
Trendline
Moderna's Cancer Vaccine Development Faces Market Scrutiny and Regulatory Hurdles
Moderna's Cancer Vaccine Development Faces Market Scrutiny and Regulatory Hurdles
Read More
Trendline
Mondelez International Reaffirms 2026 Outlook, Projects $3 Billion Free Cash Flow
Mondelez International Reaffirms 2026 Outlook, Projects $3 Billion Free Cash Flow
Read More
Trendline
Charles River Laboratories Stock Surges Over 100% Amid Strong DSA Prospects
Charles River Laboratories Stock Surges Over 100% Amid Strong DSA Prospects
Read More
Trendline
Cisco Stock Falls Despite Record Revenue Growth, Raising Dividend Safety Questions
Cisco Stock Falls Despite Record Revenue Growth, Raising Dividend Safety Questions
Read More
Trendline
Merck Co. Experiences Stock Surge Amidst Mixed Q3 2026 Financials and Analyst Disagreement
Merck Co. Experiences Stock Surge Amidst Mixed Q3 2026 Financials and Analyst Disagreement
Read More
Trendline
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Read More
Trendline
Privia Health Reports $374 Million in Medicare Shared Savings, Increases 2026 Financial Guidance
Privia Health Reports $374 Million in Medicare Shared Savings, Increases 2026 Financial Guidance
Read More
Trendline
Bristol Myers Squibb's Growth Portfolio Reaches $7.7 Billion Amidst Investor Caution Over Eliquis Generic Competition
Bristol Myers Squibb's Growth Portfolio Reaches $7.7 Billion Amidst Investor Caution Over Eliquis Generic Competition
Read More
Trendline
CRISPR Therapeutics Stock Could Be Undervalued Despite Recent Data, Analysts Suggest
CRISPR Therapeutics Stock Could Be Undervalued Despite Recent Data, Analysts Suggest
Read More